35.5% Above Target

NMR's consensus price target is $5.79, -35.5% below the current price of $8.97. The 9 analysts tracking NMR see downside risk at present valuations.

NMR has a consensus rating of "Hold" based on 9 Wall Street analysts. The rating breakdown is mixed, with 6 Hold ratings making up the largest segment. The consensus 12-month price target of $5.79 implies -35.5% downside from current levels.

With a forward P/E of 0.0687x, NMR trades at a relatively low valuation. The consensus target of $5.79 implies -35.5% move, suggesting the market may be pricing in risks.

The most bullish Wall Street analyst has a price target of $5.79 for NMR, while the most conservative target is $5.79. The consensus of $5.79 represents the median expectation. Our quantitative valuation model projects a bull case target of $2355 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.

NMR is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 6 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.

The 12-month NMR stock forecast based on 9 Wall Street analysts shows a consensus price target of $5.79, with estimates ranging from $5.79 (bear case) to $5.79 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $1787, with bear/bull scenarios of $1126/$2355.

Our quantitative valuation model calculates NMR's fair value at $1787 (base case), with a bear case of $1126 and bull case of $2355. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 43/100.

NMR trades at a forward P/E ratio of 0.1x based on next-twelve-months earnings estimates compared to a trailing P/E of 12.1x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.

Analysts are cautious on NMR, with 0 Sell ratings and a price target of $5.79 (-35.5% from current price). The "Hold" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.

NMR analyst price targets range from $5.79 to $5.79, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $5.79 consensus represents the middle ground. Our model's $1126-$2355 range provides an independent fundamental perspective.